Sonata Therapeutics News and Activities

Sonata Therapeutics is owned by Flagship Pioneering.

Flagship Pioneering has 3 subsidiaries including Etiome, Pioneering Medicines and Sonata Therapeutics.

They are in:

• Biotechnology75%
• Fund25%

View the org chart displaying its 12 main executives

Most searched biographies at Sonata Therapeutics

• Volker Herrmann, Chief Executive Officer and President
• David Khougazian, Chairman of the Board
• Michael Rosenblatt, Director

Popular executive movements at Flagship Pioneering

• John Cuozzo has joined the company as Senior Vice President, Head of Research  (posted on November 19 2025).

Create your alert
to follow the executive moves at Sonata Therapeutics.

Flagship Pioneering has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Sonata Therapeutics

Social media about Sonata Therapeutics

• Sonata Therapeutics on Wikipedia, Google News & Yahoo Finance
• Sonata Therapeutics on LinkedIn, X (Twitter) & YouTube